연구동향 분석

아밀로이드 표적 알츠하이머치매 치료제

이애영 2021년

논문상세정보
인용/피인용
' 아밀로이드 표적 알츠하이머치매 치료제' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Amyloid β
  • Immunotherapy
  • alzheimer's disease
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
268 0

0.0%

' 아밀로이드 표적 알츠하이머치매 치료제' 의 참고문헌

  • The cholinergic hypothesis of geriatric memory dysfunction
    Bartus R [1982]
  • The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
    Sevigny J [2016]
  • The amyloid hypothesis of Alzheimer’s disease at 25 years
    Selkoe DJ [2016]
  • Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
  • Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
    Orgogozo JM [2003]
  • Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo BP [2012]
  • Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
  • Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: a systematic review and network meta-analysis
    Foroutan N [2019]
  • Request for an Office of Inspector General investigation of the FDA’s inappropriate close collaboration with Biogen before and after the submission of the biologics license application for aducanumab for treatment of Alzheimer’s disease
  • Rationale for use of the clinical dementia rating sum of boxes as a primary outcome measure for Alzheimer’s disease clinical trials
  • Post-hoc analysis could give new life to the Alzheimer's drug aducanumab
    Arnold C [2020]
  • Phase 3 trials of solanezumab for mild-tomoderate Alzheimer’s disease
    Doody RS [2014]
  • Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression
    Tolar M [2021]
  • National Institute of Dementia
  • Long‐term effects of Abeta42 immunization in Alzheimer's disease:follow‐up of a randomised, placebo‐controlled phase I trial
    Holmes C [2008]
  • Inhibition of amyloid-beta aggregation in Alzheimer's disease
    Wang Q [2014]
  • Gantenerumab reduces amyloid-beta plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
    Klein G [2019]
  • Gantenerumab for the treatment of Alzheimer's disease
    Delrieu J [2012]
  • Evaluation of aducanumb for Alzheimer disease. Scientific evidence and regulatory review involving efficacy, safety, and futility
  • Emerge and engage topline results: phase 3 studies of aducanumab in early Alzheimer’s disease
  • Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis
    Shinji M [2019]
  • Donanemab in early Alzheimer’s disease
    Mintun MA [2021]
  • Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
    Andrews JS [2019]
  • Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain
    Hey JA [2018]
  • Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain
    Hong W [2018]
  • Demonstrating substantial evidence of effectiveness for human drug and biological products
  • Characteristics of single pivotal trials supporting regulatory approvals of novel non-orphan, non-oncology drugs in the European Union and United States from 2012-2016
    Morant AV [2019]
  • Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on new analysis of larger dataset from phase 3 studies
  • Biogen and eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab in Alzheimer’s disease
  • Bapineuzumab: anti‐beta‐amyloid monoclonal antibodies for the treatment of Alzheimer's disease
    Panza F [2010]
  • BACE-1 and gamma-secretase as therapeutic targets for Alzheimer's disease
    Maria MA [2019]
  • Aβ immunotherapy for Alzheimer's disease
    Sakai K [2013]
  • Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study
    Hanseeuw BJ [2019]
  • Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid peptide
    Hashimoto T [2012]
  • Anti-amyloid-β protein agents for the treatment of Alzheimer's disease:an update on emerging drugs
    Lozupone M [2020]
  • Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise
    van Dyck CH [2018]
  • Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup
    Sperling R [2011]
  • Alzheimer’s disease: the amyloid cascade hypothesis
    Hardy JA [1992]
  • Alzheimer’s disease: recent treatment strategies
    Vaz M [2020]
  • Alzheimer disease: an update on pathobiology and treatment strategies
    Long JM [2019]
  • Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
    Cummings J [2021]
  • Addendum: the antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
    Sevigny J [2017]
  • A systematic review of antiamyloidogenic and metal-chelating peptoids: two structural motifs for the treatment of Alzheimer's disease
    Young SC [2018]
  • A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody
    Swanson CJ [2021]
  • A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
  • A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
    Panza F [2019]
  • 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)
  • 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)